Febrile neutropenia in children with cancer: A retrospective Norwegian multicentre study of clinical and microbiological outcome

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 4, 2008, Pages 301-307

  Stabell, Niklas ^a   Nordal, Ellen ^a   Stensvold, Einar ^b   Gammelsrud, Karianne Wiger ^b   Lund, Bendik ^c   Taxt, Arne ^d   Buhring, Frauke ^e   Greve Isdahl, Margrethe ^f   Fornebo, Hans Petter ^g   Simonsen, Gunnar Skov ^a,h   Klingenberg, Claus ^a,i  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e Dept Anaesthesia/Intensive Care M   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g VESTFOLD HOSPITAL TRUST   (Norway)

^h NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

ⁱ UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; FLUCONAZOLE; GENTAMICIN; PENICILLIN G; VANCOMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BLOOD CULTURE; CANDIDIASIS; CHILD; CHILDHOOD CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPIRICISM; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MYCOSIS; NORWAY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; SEPTICEMIA; STATISTICAL SIGNIFICANCE;

EID: 41349110425     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701670436     Document Type: Review

References (28)

1. Hann, I., Viscoli, C., Paesmans, M., Gaya, H. and Glauser, M. (1997) A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol, 99, pp. 580-588.
2. Ammann, RA, Hirt, A., Luthy, AR and Aebi, C. (2004) Predicting bacteraemia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J, 23, pp. 61-67.
3. Haslam, DB. (2002) Managing the child with fever and neutropenia in an era of increasing microbial resistance. J Pediatr, 140, pp. 5-7.
4. Corapcioglu, F., Sarper, N. and Zengin, E. (2006) Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in paediatric cancer patients: A randomized comparison. Pediatr Hematol Oncol, 23, pp. 177-186.
5. Fleischhack, G., Hartmann, C., Simon, A., Wulff, B., Havers, W. and Marklein, G. (2001) Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother, 47, pp. 841-853.
6. Sigurdardottir, K., Digranes, A., Harthug, S., Nesthus, I., Tangen, JM and Dybdahl, B. (2005) A multicentre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility. Scand J Infect Dis, 37, pp. 455-464.
7. Torfoss, D., Hoiby, EA, Tangen, JM, Holte, H., Bo, K. and Meyer, P. (2007) Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: A prospective, randomized, multicentre trial. J Antimicrob Chemother, 59, pp. 711-717.
8. Gatta, G., Capocaccia, R., Stiller, C., Kaatsch, P., Berrino, F. and Terenziani, M. (2005) Childhood cancer survival trends in Europe: A EUROCARE Working Group study. J Clin Oncol, 23, pp. 3742-3751.
9. Hughes, WT, Armstrong, D., Bodey, GP, Bow, EJ, Brown, AE and Calandra, T. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 34, pp. 730-751.
10. NWGA; Norwegian Working Group for Antibiotics.
11. Baorto, EP, Aquino, VM, Mullen, CA, Buchanan, GR and DeBaun, MR. (2001) Clinical parameters associated with low bacteraemia risk in 1100 paediatric oncology patients with fever and neutropenia. Cancer, 92, pp. 909-913.
12. Chamberlain, JD, Smibert, E., Skeen, J. and Alvaro, F. (2005) Prospective audit of treatment of paediatric febrile neutropenia in Australasia. J Paediatr Child Health, 41, pp. 598-603.
13. Basu, SK, Fernandez, ID, Fisher, SG, Asselin, BL and Lyman, G. H. (2005) Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol, 23, pp. 7958-7966.
14. Hemsworth, S., Nunn, AJ, Selwood, K., Osborne, C., Jones, A. and Pizer, B. (2005) Once-daily netilmicin for neutropenic pyrexia in paediatric oncology. Acta Paediatr, 94, pp. 268-274.
15. Vignoli, R., Calvelo, E., Cordeiro, NF, Lucero, R., Ingold, E. and Quintana, A. (2006) Association of broad-spectrum antibiotic use with faecal carriage of oxyiminocephalosporin-resistant enterobacteriaceae in an intensive care unit. J Hosp Infect, 63, pp. 306-315.
16. de Man, P., Verhoeven, BA, Verbrugh, HA, Vos, MC and Anker, JN. van den (2000) An antibiotic policy to prevent emergence of resistant bacilli. Lancet, 355, pp. 973-978.
17. Chapman, RL. (2007) Prevention and treatment of candida infections in neonates. Semin Perinatol, 31, pp. 39-46.
18. Weinberger, M., Sweet, S., Leibovici, L., Pitlik, SD and Samra, Z. (2003) Correlation between candiduria and departmental antibiotic use. J Hosp Infect, 53, pp. 183-186.
19. Bartlett, JG. (2006) Narrative review: The new epidemic of Clostridium difficile associated enteric disease. Ann Intern Med, 145, pp. 758-764.
20. Boragina, M., Patel, H., Reiter, S. and Dougherty, G. (2007) Management of febrile neutropenia in paediatric oncology patients: A Canadian survey. Pediatr Blood Cancer, 48, pp. 521-526.
21. Phillips, B., Selwood, K., Lane, S., Skinner, R., Gibson, F. and Chisholm, JC. (2007) Variation in policies for the management of febrile neutropenia in the United Kingdom Children's Cancer Study Group centres. Arch Dis Child, 92, pp. 495-498.
22. Phillips, R., Skinner, R. and Chisholm, JC. (2007) Treating low-risk febrile neutropenia: Jenny's story. Arch Dis Child, 92, pp. 7-8.
23. Bodey, GP, Jadeja, L. and Elting, L. (1985) Pseudomonas bacteraemia. Retrospective analysis of 410 episodes. Arch Intern Med, 145, pp. 1621-1629.
24. (2005) NORM/NORM-VET: Usage of Antimicrobial Agents and Occurence of Antimicrobial Resistance in Norway.
25. Simon, A., Groger, N., Wilkesmann, A., Hasan, C., Wiszniewsky, G. and Engelhart, S. (2006) Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents, 28, pp. 417-422.
26. Jones, GR, Konsler, GK, Dunaway, RP and Pusek, SN. (1996) Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol, 13, pp. 217-229.
27. Orudjev, E. and Lange, BJ. (2002) Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol, 39, pp. 77-85.
28. Santolaya, ME, Alvarez, AM, Becker, A., Cofre, J., Enriquez, N. and O'Ryan, M. (2001) Prospective, multicentre evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol., 19, pp. 3415-3421.